Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HSTC
HST Global
$1.11
+18.1%
$0.73
$0.10
$1.15
N/A-1.062,482 shs2,600 shs
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
$0.09
$0.09
$0.07
$1.30
$7.78M0.4615,246 shs12 shs
OREXQ
Orexigen Therapeutics
$0.01
+35.9%
$0.01
$0.00
$0.16
$100K4.9880,439 shs60,300 shs
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
$0.00
-9.1%
$0.00
$0.00
$0.26
$52K1.743.44 million shs3.35 million shs
SKVI
Skinvisible
$0.06
$0.08
$0.06
$0.14
$277K-0.411,605 shsN/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HSTC
HST Global
0.00%-41.96%-23.53%+22.62%+550.00%
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
0.00%0.00%0.00%0.00%-84.50%
OREXQ
Orexigen Therapeutics
0.00%0.00%0.00%0.00%0.00%
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
+10.00%+10.00%-59.26%-79.63%-99.69%
SKVI
Skinvisible
0.00%-39.60%-6.15%-12.86%-38.38%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
HSTC
HST Global
N/AN/AN/AN/AN/AN/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
SKVI
Skinvisible
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
HSTC
HST Global
N/AN/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/AN/A
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/A
SKVI
Skinvisible
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
HSTC
HST Global
N/AN/AN/AN/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/AN/A($0.03) per shareN/A
OREXQ
Orexigen Therapeutics
$33.71M0.00N/AN/AN/A
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/A($0.52) per shareN/A
SKVI
Skinvisible
$20K13.85N/AN/A($1.99) per share-0.03

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
HSTC
HST Global
-$150K-$0.04N/AN/AN/AN/A-9,797.01%N/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
-$3.54MN/A0.00N/AN/AN/A-544.75%N/A
OREXQ
Orexigen Therapeutics
-$24.52MN/A0.00N/AN/AN/AN/AN/A
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
-$2.66MN/A0.00N/AN/AN/A-1,592.49%N/A
SKVI
Skinvisible
-$2.38MN/A0.00N/A-11,915.00%N/A-1,270.51%N/A

Latest PPCB, SKVI, OREXQ, IMUN, and HSTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/5/2024Q4 2023
HSTC
HST Global
N/A-$0.01-$0.01-$0.01N/AN/A
2/20/2024Q2 2024
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
N/A-$0.03-$0.03-$0.03N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
HSTC
HST Global
N/AN/AN/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/AN/AN/A
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/AN/A
SKVI
Skinvisible
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
HSTC
HST Global
N/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/A
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
N/A
0.06
0.06
SKVI
Skinvisible
N/A
0.01
0.01

Ownership

Institutional Ownership

CompanyInstitutional Ownership
HSTC
HST Global
N/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/A
OREXQ
Orexigen Therapeutics
N/A
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
N/A
SKVI
Skinvisible
N/A

Insider Ownership

CompanyInsider Ownership
HSTC
HST Global
65.82%
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
50.59%
OREXQ
Orexigen Therapeutics
13.30%
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
1.80%
SKVI
Skinvisible
53.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
HSTC
HST Global
1N/AN/ANot Optionable
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
283.66 million41.34 millionNot Optionable
OREXQ
Orexigen Therapeutics
N/A18.89 millionN/ANot Optionable
Propanc Biopharma, Inc. stock logo
PPCB
Propanc Biopharma
152.15 million51.21 millionNot Optionable
SKVI
Skinvisible
24.54 million2.13 millionNot Optionable

PPCB, SKVI, OREXQ, IMUN, and HSTC Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

HST Global

OTCMKTS:HSTC
HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer in the United States and internationally. The company also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancers and other life-threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.
Immune Therapeutics logo

Immune Therapeutics

OTCMKTS:IMUN
Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.

Orexigen Therapeutics

OTCMKTS:OREXQ
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Propanc Biopharma logo

Propanc Biopharma

OTCMKTS:PPCB
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Skinvisible

OTCMKTS:SKVI
Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over the counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company offers sunless tanning and sunscreen products. It also licenses to pharmaceutical companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.